GPLD1 and neoplasm: However, while DXR delivery to tumor by D31-PLD after 12 h of injection was half of what was delivered by non-targeted or single-peptide-modified preparations, the antitumor efficacy was significantly greater than P-PLD, T2-PLD, and D32-PLD.